Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/41292

3'-Azido-3'-deoxythymidine (AIDS): Target Organs and Levels of Evidence for GMM-16

Toxicology and Carcinogenicity Study of Mixtures of 3′-Azido-3′-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRN 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
3'-Azido-3'-deoxythymidine (AIDS)
30516-87-1
(AZT/3TC/NVP- L,M,H)
Gavage
AZT/3TC: 0, 240, or 150 mg/kg bw/day - AZT/3TC/NVP combo for P53 mice: AZT: 0, 80, 160, or 240 mg/kg bw/day; 3TC: 0, 50, 100, or 150 mg/kg bw/day; NVP 1-3: 0, 56, 112, or 168 mg/kg bw/day; 1/8 dose NVP PND 1-3 and 1/2 dose NVP PND 4-10
National Center for Toxicological Research

Levels of Evidence

Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: hepatocellular adenoma 1/25, 7/25, 7/23, 9/23; hepatocellular adenoma or carcinoma 1/25, 9/25, 8/23, 10/23
  • Liver: hepatocellular adenoma 1/25, 9/25; hepatocellular adenoma or carcinoma 1/25, 10/25
May Have Been Related
  • All Organs: malignant lymphoma 1/25, 3/25
    Female Mice: Equivocal Evidence
    Type Organ/Tissue (Lesion)
    May Have Been Related
    • All Organs: malignant lymphoma 2/25, 2/25, 4/22, 4/25
    • All Organs: malignant lymphoma 2/25, 4/24
    • Mammary Gland: adenoacanthoma or adenocarcinoma 1/25, 4/25


    Chemical (Study Title)
    CASRN
    Peer Review Date Route/Exposure Levels Study Laboratory
    3'-Azido-3'-deoxythymidine (AIDS)
    30516-87-1
    02/00/2012 Gavage
    AZT/3TC: 0, 240, or 150 mg/kg bw/day -- AZT/3TC/NVP combo for P53 mice: AZT: 0, 80, 160, or 240 mg/kg bw/day; 3TC: 0, 50, 100, or 150 mg/kg bw/day; NVP 1-3: 0, 56, 112, or 168 mg/kg bw/day; 1/8 dose NVP PND 1-3 and 1/2 dose NVP PND 4-10
    National Center for Toxicological Research

    Levels of Evidence

    Male Mice: Clear Evidence
    Type Organ/Tissue (Lesion)
    Neoplastic Lesions
    • Liver: hepatocellular adenoma 1/25, 8/23
    May Have Been Related
    • All Organs: malignant lymphoma 1/25, 3/24
    Female Mice: No Evidence


    Chemical (Study Title)
    CASRN
    Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
    3'-Azido-3'-deoxythymidine (AIDS)
    30516-87-1
    (NVP-H)
    02/00/2012 Pyrimidine nucleoside analog with antiviral activity used in the treatment of AIDS (Merck 1989) Gavage
    AZT/3TC: 0, 240, or 150 mg/kg bw/day -AZT/3TC/NVP combo for P53 mice: AZT: 0, 80, 160, or 240 mg/kg bw/day; 3TC: 0, 50, 100, or 150 mg/kg bw/day; NVP 1-3: 0, 56, 112, or 168 mg/kg bw/day; 1/8 dose NVP PND 1-3 and 1/2 dose NVP PND 4-10
    National Center for Toxicological Research

    Levels of Evidence

    Male Mice: No Evidence
    Female Mice: Equivocal Evidence
    Type Organ/Tissue (Lesion)
    May Have Been Related
    • All Organs: malignant lymphoma 2/25, 5/25


    Chemical (Study Title)
    CASRN
    Peer Review Date Route/Exposure Levels Study Laboratory
    AZT+3TC+NVP combination
    AZT3TCCOMBO
    02/00/2012 Gavage
    25 animals/group; Dose combinations AZT, 3TC, NVP, AZT/3TC, AZT/3TC/NVP
    National Center for Toxicological Research

    Levels of Evidence: None